A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Leukemia

• Publication date

  2003-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.leu.2402752PMID 12592330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma

  2002cited by this paper
• CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

  2001cited by this paper
• Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

  2001cited by this paper
• Rituximab dose-escalation trial in chronic lymphocytic leukemia.

  2001cited by this paper
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• Novel therapies for chronic lymphocytic leukemia in the 21st century.

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study

  1999cited by this paper
• Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

  1999cited by this paper
• Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

  1999cited by this paper
• Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocyte leukemia

  1999cited by this paper
• Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

  1999cited by this paper
• Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes.

  1998cited by this paper
• Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

  1998cited by this paper
• p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.

  1998cited by this paper
• Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

  1997cited by this paper
• 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.

  1997cited by this paper
• Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.

  1996cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Infectious and immunosuppressive complications of purine analog therapy.

  1995cited by this paper
• p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

  1995cited by this paper
• Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.

  1995cited by this paper
• 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.

  1994cited by this paper
• Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.

  1994cited by this paper
• 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

  1993cited by this paper
• High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.

  1993cited by this paper
• 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

  1993cited by this paper
• Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1992cited by this paper
• Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

  1991cited by this paper
• Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer.

  1990cited by this paper
• Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

  1989cited by this paper
• Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

  1989cited by this paper
• Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.

  1988cited by this paper
• 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

  1988cited by this paper
• Low-dose deoxycoformycin in lymphoid malignancy.

  1985cited by this paper
• A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

  1981cited by this paper
• Clinical staging of chronic lymphocytic leukemia.

  1975cited by this paper

• Chronic Lymphocytic Leukemia

  2019cites this paper
• Assays on DNA Damage and Repair in CLL.

  2018cites this paper
• Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature

  2017cites this paper
• A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia

  2016cites this paper
• Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK‐LGL leukaemia

  2015cites this paper
• Studies of overcoming acquired resistance : molecular mechanisms and development of novel drugs

  2014cites this paper
• Infections in patients with leukemia and lymphoma.

  2014cites this paper
• The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

  2012cites this paper
• Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

  2011cites this paper
• Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

  2010cites this paper
• Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.

  2010cites this paper
• Managing Infections in Patients With Hematological Malignancies

  2010cites this paper
• Chronic lymphocytic leukemia.

  2010cites this paper
• Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options

  2010cites this paper
• Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

  2010cites this paper
• Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma

  2010cites this paper
• Chapter 4 Fungal and Parasitic Infections

  2009cites this paper
• Cladribine: not just another purine analogue?

  2009cites this paper
• Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis.

  2009cites this paper
• Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion

  2009cites this paper
• Drug cross‐resistance and therapy‐induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing

  2009cites this paper
• Fungal and Parasitic Infections

  2009cites this paper
• Infectious Complications in Patients with Chronic Lymphocytic Leukemia

  2008cites this paper
• Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2008cites this paper
• Recent progress in the management of chronic lymphocytic leukemia.

  2007cites this paper
• Chronic Lymphocytic Leukemia and Psychoneuroimmunology

  2007cites this paper
• Management of infectious complications in patients with chronic lymphocytic leukemia.

  2007cites this paper
• Recent Advances in Chronic Lymphocytic Leukemia

  2006cites this paper
• The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.

  2006cites this paper
• Plasma cell dyscrasias and leukemias.

  2006cites this paper
• Chronic lymphocytic leukemia: diagnosis and treatment.

  2006cites this paper
• Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia

  2006cites this paper
• Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

  2006cites this paper
• Role of fludarabine in hematological malignancies

  2006cites this paper
• [Infectious complications as a consequence of treatment with nucleoside analogs and monoclonal antibodies].

  2006cites this paper
• Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.

  2006cites this paper
• A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma

  2006cites this paper
• Chronic lymphocytic leukemia: recent advances in diagnosis and treatment.

  2006cites this paper
• Infektiöse Komplikationen als Folge der Behandlung mit Nukleosidanaloga und monoklonalen Antikörpern

  2006cites this paper
• Immunomodulating drugs for chronic lymphocytic leukaemia.

  2006cites this paper
• Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

  2006cites this paper
• Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

  2005cites this paper
• Infections associated with purine analogs and monoclonal antibodies.

  2005cites this paper
• Biology and treatment of chronic lymphocytic leukemia.

  2005cites this paper
• Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues

  2005cites this paper
• Advances in the diagnosis and treatment of chronic lymphocytic leukemia

  2005cites this paper
• Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies

  2005cites this paper
• Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

  2004cites this paper
• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

  2004cites this paper
• Chronic lymphocytic leukemia.

  2004cites this paper
• An update on the management of chronic lymphocytic leukaemia

  2004cites this paper